Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.
Gilead’s Vienna office opened in 2007. It is responsible for Gilead’s commercial operations in Austria. The team is committed to offering and maintaining high-quality service to the medical community and is focused on the distribution of our products throughout the country.
Contact
Wagramer Strasse 19, 1220 Vienna
Tel +43 (0) 1 260 83-0
Website http://www.gilead.com/
Despite its modest market size, Taiwan is proving a popular investment destination for pharma and medtech multinationals. While the island’s semiconductor industry garners more headlines and revenues, life sciences is…
CAR T-cell therapies are entering a new phase of development in which the focus is increasingly shifting from scientific validation towards the practical realities of access, scalability, reimbursement, and delivery…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
Arturo De la Rosa, Vice President for Latin America at Gilead Sciences, leverages deep regional experience to navigate healthcare challenges and opportunities across multiple countries. He oversees a dual strategy,…
With more than 20 years of experience in the pharmaceutical industry and a track record at companies such as MSD, Abbott (later AbbVie), Eisai and AstraZeneca, Stuart Head brings a…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could…
Gilead’s Mexican affiliate is its largest in the LatAm region, and one that has had an impressive impact as 85 percent of those living with HIV in the country are…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
See our Cookie Privacy Policy Here
